Jump to main content
Jump to site search

Issue 18, 2018
Previous Article Next Article

Design, physico-chemical and pre-clinical evaluation of a homo-bivalent 99mTc-(BTZ)2DTPA radioligand for targeting dimeric 5-HT1A/5-HT7 receptors

Author affiliations

Abstract

A mixed affinity dimeric radioligand 99mTc-(BTZ)2DTPA was designed using a “bivalent ligand approach” and evaluated as an SPECT imaging agent for targeting 5-HT1A/5-HT7 dimeric receptors in the central nervous system. In silico studies reflected high affinity for dimeric 5-HT1A/5-HT7 receptors. Following multi-step synthesis, the ligand was obtained in 87.5% yield. Detailed physico-chemical analysis included pKa evaluation and optimization of radiolabeling parameters (>98% radiolabeling efficiency). The in vitro serum-stability test of the 99mTc-complex showed ≤8.7% dissociation and appreciable stability when challenged with excess cysteine (≤4.4% dissociation). Cyto-compatibility (4.8–0.6% cell death at 100 μM to 1 pM) and haemo-compatibility (1.05% erythrocyte destruction) suggested optimum biocompatibility. Blood kinetics revealed biphasic clearance. The brain/blood ratio of 0.66 assured the CNS penetration ability and BBB permeability of the developed radioligand. Bio-distribution and in vivo SPECT imaging revealed a maximum brain uptake of 2.08 ± 0.08% ID per g at 10 min p.i. followed by major activity accumulation in 5-HT1A/5-HT7 receptor-rich regions viz., the hippocampus (41.83% ID per g) and the cortex (23.56% ID per g) of mouse brains ascertaining selective targeting of 99mTc-(BTZ)2DTPA. The radiotracer was excreted majorly through the renal route. These preclinical studies reveal that the 99mTc-(BTZ)2DTPA radiotracer shows promise as an effective diagnostic agent for neurological disorders.

Graphical abstract: Design, physico-chemical and pre-clinical evaluation of a homo-bivalent 99mTc-(BTZ)2DTPA radioligand for targeting dimeric 5-HT1A/5-HT7 receptors

Back to tab navigation

Supplementary files

Publication details

The article was received on 07 Jan 2018, accepted on 20 Jul 2018 and first published on 16 Aug 2018


Article type: Paper
DOI: 10.1039/C8NJ00089A
Citation: New J. Chem., 2018,42, 15032-15043
  •   Request permissions

    Design, physico-chemical and pre-clinical evaluation of a homo-bivalent 99mTc-(BTZ)2DTPA radioligand for targeting dimeric 5-HT1A/5-HT7 receptors

    P. Jha, S. Chaturvedi, A. Kaul, P. Pant, Anju, S. Pal, N. Jain and A. K. Mishra, New J. Chem., 2018, 42, 15032
    DOI: 10.1039/C8NJ00089A

Search articles by author

Spotlight

Advertisements